Cargando…

XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis

ABSTRACT: BACKGROUND: Published studies investigating the association between XPC Lys939Gln polymorphism and colorectal cancer (CRC) risk reported inconclusive results. We performed a meta-analysis to derive a precise estimation of the relationship. METHODS: A comprehensive literature search was don...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Qiliu, Lao, Xianjun, Tang, Weizhong, Chen, Zhiping, Li, Ruolin, Qin, Xue, Li, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098961/
https://www.ncbi.nlm.nih.gov/pubmed/24947936
http://dx.doi.org/10.1186/1746-1596-9-120
_version_ 1782326409680650240
author Peng, Qiliu
Lao, Xianjun
Tang, Weizhong
Chen, Zhiping
Li, Ruolin
Qin, Xue
Li, Shan
author_facet Peng, Qiliu
Lao, Xianjun
Tang, Weizhong
Chen, Zhiping
Li, Ruolin
Qin, Xue
Li, Shan
author_sort Peng, Qiliu
collection PubMed
description ABSTRACT: BACKGROUND: Published studies investigating the association between XPC Lys939Gln polymorphism and colorectal cancer (CRC) risk reported inconclusive results. We performed a meta-analysis to derive a precise estimation of the relationship. METHODS: A comprehensive literature search was done in databases PubMed, EMBASE, and Cochrane library up to December 2013. The association between XPC Lys939Gln polymorphism and CRC risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs). RESULTS: Eight studies with 3,301 cases and 4,177 controls were included in the meta-analysis. We observed that the XPC Lys939Gln polymorphism was correlated with an increased CRC risk when all studies were pooled into the meta-analysis (Gln/lys vs. Lys/Lys: OR = 1.293, 95% CI 1.169–1.430, P = 0.000; Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.260, 95% CI 1.145–1.388, P = 0.000). In stratified analyses by ethnicity, smoking, and study quality, significant increased CRC risk was found in Asians (Gln/lys vs. Lys/Lys: OR = 1.345, 95% CI 1.187–1.523, P = 0.000; Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.317, 95% CI 1.170–1.484, P = 0.000), nonsmokers (Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.286, 95% CI 1.020–1.622, P = 0.033), and high quality studies. In subgroup analysis by source of control, significant increased CRC risk was found in both hospital-based studies and population-based studies. However, in subgroup analysis according to cancer location, no any significant association was detected. CONCLUSIONS: This meta-analysis suggests that the XPC is a candidate gene for CRC susceptibility. The XPC Lys939Gln polymorphism may play an important role in CRC development among Asians and nonsmokers. Further large and well-designed studies are needed to confirm this association. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1665902729125948
format Online
Article
Text
id pubmed-4098961
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40989612014-07-16 XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis Peng, Qiliu Lao, Xianjun Tang, Weizhong Chen, Zhiping Li, Ruolin Qin, Xue Li, Shan Diagn Pathol Review ABSTRACT: BACKGROUND: Published studies investigating the association between XPC Lys939Gln polymorphism and colorectal cancer (CRC) risk reported inconclusive results. We performed a meta-analysis to derive a precise estimation of the relationship. METHODS: A comprehensive literature search was done in databases PubMed, EMBASE, and Cochrane library up to December 2013. The association between XPC Lys939Gln polymorphism and CRC risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs). RESULTS: Eight studies with 3,301 cases and 4,177 controls were included in the meta-analysis. We observed that the XPC Lys939Gln polymorphism was correlated with an increased CRC risk when all studies were pooled into the meta-analysis (Gln/lys vs. Lys/Lys: OR = 1.293, 95% CI 1.169–1.430, P = 0.000; Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.260, 95% CI 1.145–1.388, P = 0.000). In stratified analyses by ethnicity, smoking, and study quality, significant increased CRC risk was found in Asians (Gln/lys vs. Lys/Lys: OR = 1.345, 95% CI 1.187–1.523, P = 0.000; Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.317, 95% CI 1.170–1.484, P = 0.000), nonsmokers (Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.286, 95% CI 1.020–1.622, P = 0.033), and high quality studies. In subgroup analysis by source of control, significant increased CRC risk was found in both hospital-based studies and population-based studies. However, in subgroup analysis according to cancer location, no any significant association was detected. CONCLUSIONS: This meta-analysis suggests that the XPC is a candidate gene for CRC susceptibility. The XPC Lys939Gln polymorphism may play an important role in CRC development among Asians and nonsmokers. Further large and well-designed studies are needed to confirm this association. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1665902729125948 BioMed Central 2014-06-19 /pmc/articles/PMC4098961/ /pubmed/24947936 http://dx.doi.org/10.1186/1746-1596-9-120 Text en Copyright © 2014 Peng et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Peng, Qiliu
Lao, Xianjun
Tang, Weizhong
Chen, Zhiping
Li, Ruolin
Qin, Xue
Li, Shan
XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis
title XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis
title_full XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis
title_fullStr XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis
title_full_unstemmed XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis
title_short XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis
title_sort xpc lys939gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098961/
https://www.ncbi.nlm.nih.gov/pubmed/24947936
http://dx.doi.org/10.1186/1746-1596-9-120
work_keys_str_mv AT pengqiliu xpclys939glnpolymorphismcontributestocolorectalcancersusceptibilityevidencefromametaanalysis
AT laoxianjun xpclys939glnpolymorphismcontributestocolorectalcancersusceptibilityevidencefromametaanalysis
AT tangweizhong xpclys939glnpolymorphismcontributestocolorectalcancersusceptibilityevidencefromametaanalysis
AT chenzhiping xpclys939glnpolymorphismcontributestocolorectalcancersusceptibilityevidencefromametaanalysis
AT liruolin xpclys939glnpolymorphismcontributestocolorectalcancersusceptibilityevidencefromametaanalysis
AT qinxue xpclys939glnpolymorphismcontributestocolorectalcancersusceptibilityevidencefromametaanalysis
AT lishan xpclys939glnpolymorphismcontributestocolorectalcancersusceptibilityevidencefromametaanalysis